6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Author(s) Pre or Post Print Version
32 results
-
-
Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
Author(s) Pre or Post-Print Version Only
-
Modelling the radiobiological effect of intraoperative X-ray brachytherapy for breast cancer using an air-filled spherical applicator
Open Access
-
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
This article is available under the terms of the Creative Commons Attribution License (CC BY).
-
Current trends in breast surgery.
-
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Available on publishers website: https://clincancerres.aacrjournals.org/content/26/7/1574
-
Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
-
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
-
Occult breast carcinoma in breast reduction specimens in European women.
Author(s) Pre Print and Post Print Only
-
Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT.
-
The impact of "Be Clear on Cancer" campaign on breast care services provided by a specialist oncoplastic unit - A retrospective case control study.
-
Symmetrisation procedures in breast reconstruction patients constitute a rising workload in our DGH.
-
Axillary treatment for patients with early breast cancer and lymph node metastasis: systematic review protocol.
-
Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT.
Publisher version available.
-
Axillary conservation in early breast cancer.
Author(s) Pre Print Only
-
A literature review: The role of plakoglobin as a biomarker to determine the invasive potential of ductal carcinoma in situ
-
Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study.
Author(s) Pre or Post Print Version Only
-
Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT).
-
Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?
-
Evaluation of patient-centred communication in breast clinic; how are we doing and what we need to improve?